These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 19404524

  • 1. Response to DDAVP in children with von Willebrand disease type 2.
    Schneppenheim R, Budde U, Beutel K, Hassenpflug WA, Hauch H, Obser T, Oyen F, Schneppenheim S, Schrum J.
    Hamostaseologie; 2009 May; 29(2):143-8. PubMed ID: 19404524
    [Abstract] [Full Text] [Related]

  • 2. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A, Berneman Z, Schroyens W, Michiels JJ.
    Acta Haematol; 2009 May; 121(2-3):128-38. PubMed ID: 19506359
    [Abstract] [Full Text] [Related]

  • 3. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ.
    Acta Haematol; 2009 May; 121(2-3):71-84. PubMed ID: 19506352
    [Abstract] [Full Text] [Related]

  • 4. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 5. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [Abstract] [Full Text] [Related]

  • 6. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ, Thom J, Patterson D, Just S, Dixon T, Koutts J, Baccala M, Rowell J, Baker R.
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [Abstract] [Full Text] [Related]

  • 7. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ, van de Velde A, van Vliet HH, van der Planken M, Schroyens W, Berneman Z.
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [Abstract] [Full Text] [Related]

  • 8. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ, Gadisseur A, Vangenegten I, Schroyens W, Berneman Z.
    Acta Haematol; 2009 Apr; 121(2-3):119-27. PubMed ID: 19506358
    [Abstract] [Full Text] [Related]

  • 9. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A, van der Planken M, Schroyens W, Berneman Z, Michiels JJ.
    Acta Haematol; 2009 Apr; 121(2-3):145-53. PubMed ID: 19506361
    [Abstract] [Full Text] [Related]

  • 10. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
    Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van Vliet HH.
    Acta Haematol; 2009 Apr; 121(2-3):85-97. PubMed ID: 19506353
    [Abstract] [Full Text] [Related]

  • 11. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
    Akin M, Karapinar DY, Balkan C, Ay Y, Kavakli K.
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
    [Abstract] [Full Text] [Related]

  • 12. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ, van Vliet HH.
    Acta Haematol; 2009 Oct; 121(2-3):154-66. PubMed ID: 19506362
    [Abstract] [Full Text] [Related]

  • 13. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
    Sharthkumar A, Greist A, Di Paola J, Winay J, Roberson C, Heiman M, Herbert S, Parameswaran R, Shapiro A.
    Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
    [Abstract] [Full Text] [Related]

  • 14. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).
    Federici AB.
    Haemophilia; 2008 Jan; 14 Suppl 1():5-14. PubMed ID: 18173689
    [Abstract] [Full Text] [Related]

  • 15. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH, Kappers-Klunne MC, Leebeek FW, Michiels JJ.
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [Abstract] [Full Text] [Related]

  • 16. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [Abstract] [Full Text] [Related]

  • 17. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA.
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [Abstract] [Full Text] [Related]

  • 18. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velden A, Berneman Z.
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [Abstract] [Full Text] [Related]

  • 19. [Von Willebrand disease: characteristics and response to desmopressin. Study of 103 cases].
    César JM, Avello AG, Vecino A, Cerveró C, Laraña JG, Fuertes IF, Villarrubia J, López J, de Oteyza JP, Velasco JL, Cantalapiedra A, Herrera P, Herrero S, Navarro JL.
    Med Clin (Barc); 1998 Nov 14; 111(16):601-3. PubMed ID: 9881332
    [Abstract] [Full Text] [Related]

  • 20. Management of inherited von Willebrand disease in 2007.
    Federici AB, Mannucci PM.
    Ann Med; 2007 Nov 14; 39(5):346-58. PubMed ID: 17701477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.